Originally published as JCO Early Release 10.1200/JCO.2004.07.015 on February 9 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greene, F. L. Articles by Norton, H. J. Search for Related Content PubMed PubMed Citation Articles by Greene, F. L. Articles by Norton, H. J. Social Bookmarking                            What's this?

New Tumor-Node-Metastasis Staging Strategy for Node-Positive (stage III) Rectal Cancer: An Analysis

From the Department of General Surgery, and the Department of Biostatistics, Carolinas Medical Center, Charlotte, NC; Cancer Program, American College of Surgeons, Chicago, IL.

Address reprint requests to Frederick L. Greene, MD, Department of General Surgery, Carolinas Medical Center, PO Box 32861, Charlotte, NC 28232-2861; e-mail: frederick.greene{at}carolinashealthcare.org

PURPOSE: The tumor-node-metastasis system for staging rectal cancer is based on invasion, number of involved nodes, and metastasis. Nodes are classified as N1 or N2 according to the number involved with metastases. Nodal positivity defines stage III regardless of depth of invasion or number of positive nodes. Our purpose was to analyze overall survival when node-positive patients were stratified into three new subsets.

METHODS: We analyzed data entered into the National Cancer Data Base for 5,987 stage III patients with rectal cancer between 1991 and 1993. Survival was calculated using three new subgroups (IIIA: T1/2, N1; IIIB: T3/4, N1; IIIC: any T, N2). Survival following surgery and adjuvant therapy was assessed. The observed survival rates were calculated and compared using the log-rank method. The Cox regression model assessed subgroup differences.

RESULTS: Five-year observed survival rates for stage III subcategories were 55.1% in IIIA; 35.3% in IIIB; and 24.5% in IIIC. Stratifying for treatment outcome, stage IIIA patients having surgery alone (n = 278) had poorer observed 5-year survival (39%) than patients treated with surgery and adjuvant chemotherapy or radiation therapy (chemo/XRT; n = 765; 60%). Similar outcomes occurred in IIIB (surgery-alone [n = 726; 21.7%] and chemo/XRT [n = 2,130; 40.9%] groups) and in IIIC (surgery-alone [n = 467; 12.2%] and chemo/XRT [n = 1,621; 28.9%] groups). Differences were significant (P < .0001) in all stages.

CONCLUSION: The traditional stage III designation of rectal cancer fails to account for invasion (T1-4) and number of involved nodes (N1, N2). The stratification of stage III patients into three subsets should be used in future analyses of rectal cancer. The effect of postoperative adjuvant therapy was beneficial in all subsets.

Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, IL.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. D. Minsky Preoperative Treatment for Upper cT3 N0 Rectal Tumors: Is It Required? ASCO Educational Book, January 1, 2009; 2009(1): 204 - 207. [Abstract] [Full Text] [PDF]

				A F van Rijn, L G M van Rossum, M Deutekom, R J F Laheij, P M M Bossuyt, P Fockens, E Dekker, and J B M J Jansen Getting adequate information across to colorectal cancer screening subjects can be difficult J Med Screen, September 1, 2008; 15(3): 149 - 152. [Abstract] [Full Text] [PDF]

				J. G. Guillem, J. A. Diaz-Gonzalez, B. D. Minsky, V. Valentini, S.-Y. Jeong, M. A. Rodriguez-Bigas, C. Coco, R. Leon, J. L. Hernandez-Lizoain, J. J. Aristu, et al. cT3N0 Rectal Cancer: Potential Overtreatment With Preoperative Chemoradiotherapy Is Warranted J. Clin. Oncol., January 20, 2008; 26(3): 368 - 373. [Abstract] [Full Text] [PDF]

				B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer Adjuvant Treatment of Colorectal Cancer CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185. [Abstract] [Full Text] [PDF]

				D. G. Haller, P. J. Catalano, J. S. Macdonald, M. A. O'Rourke, M. S. Frontiera, D. V. Jackson, and R. J. Mayer Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089 J. Clin. Oncol., December 1, 2005; 23(34): 8671 - 8678. [Abstract] [Full Text] [PDF]

				A. B. Benson III and P. J. Catalano A Rose, Is a Rose, Is a Rose...or Not J. Clin. Oncol., May 15, 2004; 22(10): 1773 - 1775. [Full Text] [PDF]